US AI In Life Sciences Market - Strategic Insights and Forecasts (2025-2030)

Description

US AI In Life Sciences Market is anticipated to expand at a high CAGR over the forecast period.

US AI In Life Sciences Market Key Highlights

• The U.S. Food and Drug Administration (FDA) approved a substantial volume of 223 AI-enabled medical devices in 2023, representing a significant year-over-year increase that directly validates and accelerates the demand for AI platforms in diagnostics and patient care management.
• The pharmaceutical industry holds the largest end-user share, with major companies increasingly integrating AI platforms into manufacturing, clinical trials, and drug discovery workflows to combat the protracted timelines and high failure rates of traditional Research & Development (R&D).
• Recent advancements in generative AI, exemplified by new model launches and strategic industry partnerships, are fundamentally altering the drug discovery and optimization segment by allowing for accelerated molecular design and target identification, creating new demand for specialized AI software.
• The FDA's issuance of draft guidance regarding the use of AI to support regulatory decision-making for drugs and biologics establishes a foundational framework that promotes, yet scrutinizes, AI credibility, driving industry demand for robust, transparent, and 'explainable' AI systems.

The convergence of biological complexity, exponential data generation, and the persistent imperative to reduce R&D costs positions the US AI in the Life Sciences market at a critical inflection point. This sector, which encompasses the application of machine learning, deep learning, and predictive analytics across the life sciences value chain—from early-stage drug discovery to post-market surveillance—is evolving from an experimental technology to an indispensable operational layer.

US AI In Life Sciences Market Analysis

Growth Drivers

The escalating volume of complex omics data—including genomics, proteomics, and clinical trial results—creates a direct and urgent demand for AI platforms capable of sophisticated analysis beyond human capacity. Traditional drug discovery's exorbitant cost and extended timeline serve as a powerful economic catalyst, driving pharmaceutical companies to adopt AI solutions to accelerate target identification and reduce failure rates. Furthermore, the rising imperative for personalized medicine compels the use of AI to analyze unique genetic profiles and patient data, which is essential for customizing treatment protocols and thus directly increases demand for AI-driven precision medicine platforms.

Challenges and Opportunities

The primary challenge constraining market demand is the substantially high initial cost of implementation, which includes investment in sophisticated hardware, specialized software, and integration with legacy systems. This high capital expenditure creates an adoption barrier, particularly for smaller biotechnology firms. Data privacy and security concerns regarding sensitive patient health information further act as a constraint, necessitating significant investment in regulatory-compliant data governance frameworks, which increases the total cost of ownership. Conversely, the opportunity lies in the burgeoning field of Generative AI and Large Language Models (LLMs). Their capability to automate knowledge management, rapidly analyze vast scientific literature, and generate novel molecular structures presents a massive, untapped demand for next-generation AI software and service integration across the entire R&D lifecycle.

Supply Chain Analysis

The supply chain for the US AI in Life Sciences market is primarily a digital ecosystem, centered on the flow of services and software rather than physical goods. The core dependencies lie in cloud service providers (e.g., AWS, Microsoft Azure, Google Cloud) and specialized AI algorithm developers. Major production hubs are concentrated in US technology clusters, facilitating a robust development and deployment cycle. Logistical complexity revolves around data management, specifically ensuring secure, interoperable, and regulatory-compliant data pipelines—a critical dependency for AI model training and validation. The market exhibits a heavy reliance on the consistent supply of high-end computing hardware, particularly specialized processors (GPUs/TPUs) essential for deep learning workloads, where geopolitical factors and trade policies, such as tariffs on advanced chips, could introduce constraints and elevate the operational costs for both AI developers and end-users. This reliance on hardware components manufactured globally could translate to higher software and service pricing, potentially hindering the rapid scaling of AI solutions across the life sciences sector.

Government Regulations

US AI In Life Sciences Market In-Depth Segment Analysis

By Application: Drug Discovery & Development

The Drug Discovery & Development segment maintains the highest demand concentration within the market, fundamentally driven by the pharmaceutical industry’s acute need to de-risk and accelerate the R&D pipeline. The primary demand driver is the proven ability of AI models to perform rapid virtual screening of millions of compounds and predict molecular interactions with high accuracy, a process that is orders of magnitude faster than traditional high-throughput screening. This capability directly addresses the challenge of identifying viable drug candidates and targets, significantly cutting down the time and cost associated with pre-clinical development. Furthermore, the incorporation of generative AI models, such as those that predict protein folding or de novo molecule design, creates a new and persistent demand for specialized software platforms that can accelerate the process from hit identification to lead optimization, moving solutions from the experimental stage into core R&D workflows. The imperative to overcome the "patent cliff" and discover novel blockbuster drugs further propels this segment's robust demand.

By End-User: Pharmaceutical and Biotechnology Companies

Pharmaceutical and Biotechnology Companies represent the single largest consuming segment, with their demand defined by the dual pressures of economic efficiency and clinical success. The central demand driver for this end-user group is the necessity to improve clinical trial design and management. AI is specifically purchased and implemented to optimize patient recruitment by identifying ideal candidates from large Electronic Health Records (EHR) datasets and to refine site selection, directly decreasing trial costs and accelerating patient enrollment timelines. Their demand profile is heavily biased toward Services and Software components—specifically, complex data integration services, predictive analytics software for biomarker detection, and cloud-based platforms for real-time monitoring of trial data.

US AI In Life Sciences Market Competitive Environment and Analysis

The US AI in Life Sciences competitive landscape is characterized by a dynamic interplay between established technology conglomerates, specialized AI-first biotech startups, and major data/analytics service providers. Competition centers on possessing superior, proprietary datasets, demonstrable clinical/R&D success, and establishing deep, long-term strategic partnerships with leading pharmaceutical firms.

• IBM-IBM, through its WatsonX platform, focuses on delivering enterprise-grade AI and data solutions. Its strategic positioning is rooted in providing secure, hybrid cloud-based AI capabilities, leveraging its deep consulting and IT integration expertise. A key product is IBM Watsonx.data, an open and governed data store built on a data lakehouse architecture, which is critical for life sciences firms to prepare and manage the vast, disparate data needed for training complex AI models.
• Veeva Systems-Veeva Systems is strategically positioned as a cloud software provider focused exclusively on the life sciences industry. Its strength lies in its comprehensive suite of applications that manage clinical, regulatory, quality, and commercial operations, forming the Veeva Development Cloud.

US AI In Life Sciences Market Recent Developments

• In February 2025, Jabil, a global manufacturing solutions provider, announced the acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO). This strategic move vertically integrates pharmaceutical development and manufacturing capabilities into Jabil's existing healthcare services.

US AI In Life Sciences Market Segmentation

• By Component
  • Hardware
  • Software
  • Services
• By Analytics Type
  • Descriptive
  • Predictive
  • Prescriptive
  • Generative AI
• By Application
  • Drug Discovery & Development
  • Clinical Trials Design & Optimization
  • Medical Diagnosis & Imaging
  • Precision & Personalized Medicine
  • Others

Table Of Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter's Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. US AI IN LIFE SCIENCES MARKET BY COMPONENT

5.1. Introduction

5.2. Hardware

5.3. Software

5.4. Services

6. US AI IN LIFE SCIENCES MARKET BY ANALYTICS TYPE

6.1. Introduction

6.2. Descriptive

6.3. Predictive

6.4. Prescriptive

6.5. Generative AI

7. US AI IN LIFE SCIENCES MARKET BY APPLICATION

7.1. Introduction

7.2. Drug Discovery & Development

7.3. Clinical Trials Design & Optimization

7.4. Medical Diagnosis & Imaging

7.5. Precision & Personalized Medicine

7.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. IBM Corporation

9.2. IQVIA

9.3. Oracle Corporation

9.4. Atomwise Inc.

9.5. Insilico Medicine Inc.

9.6. NuMedii Inc.

9.7. Nuance Communications Inc.

9.8. Insitro

9.9. Enlitic Inc.

9.10. Valo Health

9.11. Generate Biomedicines

10. APPENDIX

10.1. Currency

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key benefits for the stakeholders

10.5. Research Methodology

10.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

IBM Corporation

IQVIA

Oracle Corporation

Atomwise Inc.

Insilico Medicine Inc.

NuMedii Inc.

Nuance Communications Inc.

Insitro

Enlitic Inc.

Valo Health

Generate Biomedicines

Related Reports